Amoctin is a benzodiazepine with a pronounced sleep-inducing activity. It depresses the reticular-activating system in the brainstem by enhancing the inhibitory effect of GABA on brain cells, thus preventing excessive brain activity.
Short-term management of insomnia, Infantile spasms
Amoctin is also used to associated treatment for these conditions: Insomnia, Myoclonic seizures
|Other Names||N-desmethylnimetazepam, Nitrazepam, Nitrazépam, Nitrazepamum|
|Therapeutic Class||Benzodiazepine hypnotics|
|Manufacturer||Skylab Pharmaceuticals Ltd|
|Last Updated:||June 23, 2021 at 11:23 am|
Table Of contents
Short-term management of insomnia:
- Adult: 5 mg at night; increase to 10 mg if necessary.
- Elderly: and debilitated patients: ≤normal adult dose.
- Child: Infants: 125 mcg/kg bid; gradually increase to 250-500 mcg/kg bid.
May be taken with or without food
Hypotension, palpitation; agitation, aggressiveness, amnesia, ataxia, confusion, delusions, disorientation, dizziness, fatigue, hallucination, hangover, headache, irritability, nightmares, psychoses, rage, restlessness, sedation; rash; changes in libido; constipation, diarrhoea, excessive salivation, heartburn, nausea, vomiting; granulocytopenia, leukopenia; falling, muscle weakness; blurred or double vision; tinnitus (associated with withdrawal); aspiration, increased bronchial secretion, dyspnoea.
May induce anterograde amnesia; caution patients to have uninterrupted sleep of 7-8 hr after ingestion of dose. May impair ability to drive or operate machinery. Depression, especially if suicidal risk may be present. History of drug abuse or acute alcoholism. Hepatic and renal impairment. Respiratory disease. Debilitated patients. Patients who are at risk of falls. Children, elderly. Pregnancy and lactation.
CNS depressant effect increased with alcohol, barbiturates, TCAs, phenothiazines, morphine derivatives. Effects may be antagonised by theophylline. Increased levels/effects with probenecid. Reduced levels/effects with rifampicin. May reduce effects of levodopa.
- Avoid alcohol.
- Limit caffeine intake.
- Take with food.
15-38 hours (mean elimination half life 26 hours).
Pregnancy & Breastfeeding use
Category not classified
Myasthenia gravis, narrow-angle glaucoma, severe respiratory insufficiency, sleep apnoea syndrome, severe hepatic impairment, porphyria.
Symptoms: Somnolence, drowsiness, confusion, ataxia, impaired reflexes, coma, dyspnoea, hypotension, respiratory and cardiovascular depression.
Management: Supportive. Gastric lavage may be beneficial if performed soon after ingestion. Flumazenil may reverse benzodiazepine-induced CNS depression.
Store at room temperature. Protect from light and moisture.